ESR1 and breast adenocarcinoma: In the present paper, the cytotoxic effect of a new ABZ-PU formulation was tested in estrogen receptor positive (ER+) human breast adenocarcinoma MCF-7 cell line and estrogen receptor negative (ER−) MDA-MB-231 cell line.